Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma

Serum CYFRA 21-1 Is One of the Most Reliable Tumor Markers for Breast Carcinoma Recently, serum tumor marker CYFRA 21-1 has shown a high sensitivity and specificity in patients with breast carcinoma as well as an important usefulness in monitoring for recurrence, evaluating the efficacy of the treatment in advanced disease, and acting as an independent prognostic factor. Based on these results we tested the sensitivity of CYFRA 21-1 in patients with metastatic breast carcinoma in our institution, before using it as a marker of recurrence in early stages or in the evaluation of the therapeutic effect in advanced disease.

[1]  M. Secic,et al.  Hypothyroidism: a frequent event after radiotherapy and after radiotherapy with chemotherapy for patients with head and neck carcinoma. , 2001, Cancer.

[2]  P. Heenan,et al.  Clinical and histologic features of level 2 cutaneous malignant melanoma associated with metastasis , 2001, Cancer.

[3]  K. Hirakawa,et al.  Serum CYFRA 21‐1 is one of the most reliable tumor markers for breast carcinoma , 2000, Cancer.

[4]  C. Robson,et al.  Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. , 1998, Cytometry.

[5]  J. Thompson,et al.  Cutaneous melanomas that defy conventional prognostic indicators. , 1996, Seminars in oncology.

[6]  M. Berwick,et al.  Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study , 1996, Cancer.

[7]  Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Huang,et al.  A prospective study of hypothalamus pituitary function after cranial irradiation with or without radiosensitizing chemotherapy , 1994, Journal of endocrinological investigation.

[9]  J. Daurès,et al.  Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.

[10]  K. Lam,et al.  Effects of cranial irradiation on hypothalamic-pituitary function--a 5-year longitudinal study in patients with nasopharyngeal carcinoma. , 1991, The Quarterly journal of medicine.

[11]  T. Huang,et al.  Early effects of cranial irradiation on hypothalamic pituitary function. , 1990, Journal of the Formosan Medical Association = Taiwan yi zhi.

[12]  M. Huang,et al.  Prospective hormone study of hypothalamic-pituitary function in patients with nasopharyngeal carcinoma after high dose irradiation. , 1989, Japanese journal of clinical oncology.

[13]  C. Holman,et al.  Inter‐observer variation between pathologists in the classification of cutaneous malignant melanoma in Western Australia , 1984, Histopathology.

[14]  W. Clark,et al.  The classification of malignant melanoma and its histologic reporting , 1973, Cancer.

[15]  W. Clark,et al.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.

[16]  B. C. Tan,et al.  Hypopituitary dwarfism following radiotherapy for nasopharyngeal carcinoma. , 1966, Clinical radiology.

[17]  A. Stout,et al.  Atlas of Tumor Pathology , 1954, American journal of clinical pathology.